Percheron Therapeutics Limited has released a press release.
Response to ASX Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Letter From The Chair and Half Year Accounts
- Topline Six-Month Results From Phase IIb Study of Avicursen
- Clinical Trial Update
- Results of Share Purchase Plan
- Percheron to launch Share Purchase Plan
Later from Percheron Therapeutics
- Trading Halt
- Percheron licenses HMBD-002 from Hummingbird Bioscience
- Appendix 4E and Annual Report
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
- Quarterly Activities Report and Appendix 4C
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics